Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product (Instruments, Reagents & Kits), By Test Type (Immunodiagnostic Test and Molecular Diagnostic Test), By End User (Hospitals, Diagnostic Laboratories, and Academic and Research Institute), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$  211.3  million in 2020 and is expected to exhibit a CAGR of 10.5% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The increasing number of product approvals and launches, adoption of methicillin resistant staphylococcus aureus (MRSA) testing systems, and mergers and acquisitions by key players are the major factors that are expected to drive growth of the Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems market during the forecast period.

Product approvals by regulatory bodies are expected drive growth of the methicillin resistant Staphylococcus aureus (MRSA) testing systems market during the forecast period. For instance, in December 2019, the US Food and Drug Administration (FDA) granted marketing approval for Roche Molecular Systems’ cobas vivoDx MRSA, a diagnostic test that detects colonisation of Methicillin-resistant Staphylococcus aureus (MRSA) bacteria. The cobas vivoDx MRSA test uses a new bacteriophage technology based on bioluminescence to detect MRSA from nasal swab samples in as less as 5 hours compared to 24-48 hours for conventional culture. The cobas vivoDx MRSA diagnostic test may allow healthcare professionals to evaluate patients for colonization with MRSA bacteria more quickly than traditional culture-based techniques.

Key players are focused on development and launch of new methicillin resistant staphylococcus aureus (MRSA) testing systems in the market which is expected to contribute significantly to the methicillin resistant staphylococcus aureus (MRSA) testing systems market growth. For instance, in June 2019, Spindiag, a medtech startup company based in Germany, announced that it had expanded financing of its first Series A funding for MRSA testing systems. A proprietary microfluidic technology was first researched at the company’s main institute. Spindiag is developing a sustainable platform to diagnose infections and as a first product, a rapid test for multidrug-resistant bacteria. Furthermore, the additional money will enable industrializing the production and securing CE-IVD approval for the EU market of an MRSA (methicillin-resistant Staphylococcus aureus) rapid test is planned for launch in 2020. Spindiag intends to use US$ 4.3 million to execute its market entry in Europe in 2020.

The increasing awareness about methicillin resistant staphylococcus aureus (MRSA) infections and prevention efforts by hospitals, governments, and other organizations is expected to accelerate the methicillin resistant staphylococcus aureus (MRSA) testing systems market growth in the near future. The U.S. Department of Health and Human Services and Centers for Disease Control and Prevention are working with healthcare facilities to meet the goals in the 2013 National Action Plan to Prevent Healthcare-Associated Infections and reduce bloodstream infections caused by MRSA by 50% by 2020 using the 2015 baseline.

Browse 35 Market Data Tables and 29 Figures spread through 177 Pages and in-depth TOC on Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product (Instruments, Reagents & Kits), By Test Type (Immunodiagnostic Test, and Molecular Diagnostic Test), By End User (Hospitals, Diagnostic Laboratories, and Academic and Research Institute), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to 2027"

To know the latest trends and insights related to Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems market, click the link below:

https://www.coherentmarketinsights.com/market-insight/methicillin-resistant-staphylococcus-aureus-testing-systems-market-3803

Several market players are focused on acquisitions and mergers to expand their product portfolio and gain a maximum share in the market. For instance, in September 2017, Abbott Laboratories announced that they have completed the acquisition of Alere, Inc. for US$ 5.3 billion. With the acquisition of Alere, the company also obtained the subsidiary Arriva Medical, which is the largest mail-order diabetic supplier. This acquisition has established Abbott as the global leader in point of care testing in vitro diagnostics market and further strengthened the company's diagnostics presence.

Key Takeaways of the Methicillin Resistant Staphylococcus Aureus (MRSA) testing systems market:

  • The methicillin resistant staphylococcus aureus (MRSA) testing systems market is expected to exhibit a CAGR of xx% during the forecast period (2020-2027) owing to increasing product approvals and product launches.
  • Among product type, the instruments segment is expected to hold a major revenue share in 2027 owing to the increasing product approvals and launches. For instance, in March 2014, AdvanDx announced that it has submitted its new mecA XpressFISH test to the U.S. Food and Drug Administration for 510(k) clearance for the rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) from S. aureus positive blood cultures. This assay will provide physicians with a new way to rapidly identify MRSA enabling them to implement appropriate treatment for patients with bloodstream infections.
  • Major players operating in the methicillin resistant Staphylococcus aureus (MRSA) testing systems market are F.Hoffmann-La Roche, Becton, Dickinson and Company, Hain Lifescience GmbH, BioMérieux, 3M Company, Bio-Rad Laboratories Inc., Abacus Diagnostica, Abbott Laboratories, Puritan Medical Products, Diatherix Eurofins, LLC, Arlington Scientific Inc., AdvanDx, Genspeed Biotech GmbH, Cepheid Inc., Luminex Corporation, and R-Biopharm AG.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner